Related Experiment Video
Updated: Oct 6, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
AT-rich interactive domain 1A (ARID1A) cannot be considered a morphological marker for prostate cancer progression: A
Giovanni Tossetta1, Sonia Fantone2, Rosaria Gesuita3
1Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, Ancona, Italy; Clinica di Ostetricia e Ginecologia, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, 60123 Ancona, Italy.
Abstract:
Prostate cancer (PCa) is one of the most common cancers worldwide but it presents many subtypes and patient heterogeneity. It is necessary to discriminate localised not aggressive PCa and metastatic cancer in order to better define the personalised treatment. The identification of an appropriate biomarker to combine with Gleason grading system, that is one of the most important prognostic factors in prostate cancer outcome, remains a major clinical issue. We have tested AT-rich interactive domain 1A (ARID1A) in prostate tissue is order to verify its possible role as morphological marker for prostate cancer progression. ARID1A is a tumour suppressor protein playing a pivotal role in chromatin remodelling during transcriptional regulation. It was decreased in many cancers correlating with tumour aggressiveness. Our data shown that ARID1A had a nuclear staining and that it is significantly decreased in prostate cancers suggesting that it can be involved in this neoplasm but it is not able to discriminate prostate cancer progression.
More Related Videos
Related Concept Videos
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Non-LTR Retrotransposons
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Ras Gene
Ras is a...

